Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.
Br J Haematol. 2012 May 10
Forni GL, Perrotta S, Giusti A, Quarta G, ..., Baldini M, Rosa A, Pinto V, Palummeri E. Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, D'Ascola DG, Borgna Pignatti C, Rigano P, Filosa A, Iolascon G, Nobili B, Baldini M, Rosa A, Pinto V, Palummeri E. Br J Haematol. 2012 May 10
Osteoporosis is a noteworthy cause of morbidity in thalassemic patients. This phase II, randomized study provides evidence that the addition of biphosphonates (specifically neridronate) to calcium and vitamin D may improve bone mineral density increase. If these data are confirmed in future blinded, randomized phase III studies, neridronate...
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.